Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Lepu Scientech Medical Technology (Shanghai) Co ROCE % Related Terms
Lepu Scientech Medical Technology (Shanghai) Co ROCE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Scientech Medical Technology (Shanghai) Co ROCE % Chart
Lepu Scientech Medical Technology (Shanghai) Co Annual Data
(1) Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) has a ROCE % of 6.59% as of Dec. 2025.
Is Lepu Scientech Medical Technology (Shanghai) Co's ROCE % too high?
Lepu Scientech Medical Technology (Shanghai) Co's current ROCE % is 6.59%. The Medical Devices & Instruments industry median ROCE % is 2.93. Lepu Scientech Medical Technology (Shanghai) Co's value of 6.59% is 124.9% above this industry median. Overall, Lepu Scientech Medical Technology (Shanghai) Co has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lepu Scientech Medical Technology (Shanghai) Co's ROCE % compare to ABT and SYK?
Lepu Scientech Medical Technology (Shanghai) Co's ROCE % of 6.59% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.93. Lepu Scientech Medical Technology (Shanghai) Co's value of 6.59% is 124.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.93, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lepu Scientech Medical Technology (Shanghai) Co's current ROCE % of 6.59% is 124.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lepu Scientech Medical Technology (Shanghai) Co's current ROCE % is 6.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Scientech Medical Technology (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$44.29, compared to a current price of HK$12.18 — trading 72.5% below its estimated fair value. The current ROCE % is 6.59% and 124.9% above the Medical Devices & Instruments industry median of 2.93. Lepu Scientech Medical Technology (Shanghai) Co's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291), the current ROCE % is 6.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co stock appears to be undervalued.
The current stock price of HK$12.18 is trading 72.5% below its estimated GF Value™ of HK$44.29.
GuruFocus considers Lepu Scientech Medical Technology (Shanghai) Co to be Significantly Undervalued.
Key valuation signals for HKSE:02291:
ROCE %: 6.59%
GF Value™: HK$44.29 vs. price of HK$12.18 (72.5% below fair value)
Industry Position: 124.9% above the Medical Devices & Instruments median
No single metric tells the full story. See the HKSE:02291 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Scientech Medical Technology (Shanghai) Co Ltd is focused on the research and development, manufacture, and commercialization of heart disease interventional medical devices. The reporting segments of the Group are as follows: The Occluder business segment and The heart valve business segment. The company generates majority of its revenue from the Occluder segment which is engaged in the research and development, manufacturing and sales of interventional treatment series occluders for the defective congenital heart disease.
76GF Score
Get the complete analysis for HKSE:02291
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02291 has been successfully added to your 
